Trevena Inc (TRVN) : Vivo Capital scooped up 528,000 additional shares in Trevena Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 1,728,000 shares of Trevena Inc which is valued at $12,044,160.Trevena Inc makes up approximately 2.89% of Vivo Capital’s portfolio.
Other Hedge Funds, Including , Guggenheim Capital added TRVN to its portfolio by purchasing 41,072 company shares during the most recent quarter which is valued at $286,272. Blackrock Japan Ltd sold out all of its stake in TRVN during the most recent quarter. The investment firm sold 1,595 shares of TRVN which is valued $11,117. Dynamic Technology Lab Private Ltd sold out all of its stake in TRVN during the most recent quarter. The investment firm sold 17,110 shares of TRVN which is valued $119,257.
Trevena Inc closed down -0.01 points or -0.15% at $6.77 with 1,26,349 shares getting traded on Thursday. Post opening the session at $6.77, the shares hit an intraday low of $6.66 and an intraday high of $6.88 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
Trevena Inc. (Trevena) is a clinical-stage biopharmaceutical company. The Company discovers develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform the Company has identified and advanced three differentiated product candidates: TRV130 a small molecule G protein biased ligand at the mu-opioid receptor to treat patients experiencing moderate to severe acute pain where IV administration is preferred; TRV734 a small molecule G protein biased ligand at the mu-opioid receptor to treat moderate to severe acute and chronic pain and TRV027 a peptide b-arrestin biased ligand that targets the angiotensin II type 1 receptor (AT1R) inhibiting G protein signaling and activating b-arrestin signaling. The Company has also identified a new product candidate TRV250 a small molecule G protein biased ligand of the delta-opioid receptor program focused on central nervous system (CNS).